Navigating an Increasingly Complex Treatment Landscape in Moderate-to-Severe Rheumatoid Arthritis (RA): Improving Clinical and Economic Outcomes with Biomarkers and Individualized Management

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Bristol-Myers Squibb

Description:
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fortunately for patients with RA, several new medications have become available recently. Diagnosis is done through examination, including x-rays and ultrasounds, and blood testing for certain indications and to rule out other possible causes for the symptoms. There is no cure for RA, treatment is to control the pain, during flair ups especially, and to prevent joint damage.

Treatment regimens vary and carry important differences between therapeutic options that are clinically relevant to healthcare professionals. An understanding of the pathogenesis of RA and the role of different treatment approaches, including current and emerging therapies, will assist healthcare providers in determining the best course of therapeutic management for optimal long-term patient outcomes. RA treatment focuses on controlling the disease and its symptoms. However, with all of the currently available non-biologic and biologic therapies, only about 1/3 of patients treated for RA ever achieve clinical remission. Fortunately, new and emerging treatment strategies have offered additional therapeutic options to address the unmet needs of these patients. Clinicians have recently been equipped with more treatment options, including new biologic DMARDs, which have demonstrated an improved efficacy and safety.

Upon completion of this activity, participants will be able to:

  • Assess the role of anti-citrullinated protein antibodies (ACPAs), among other RA biomarkers, as part of the pathophysiology of RA

  • Explore efficacy and safety profiles of current and emerging biologic therapies for the treatment of moderate-to-severe RA for achieving individualized treatment goals

  • Critically evaluate data regarding the utility of RA biomarkers, such as ACPAs, and their assays in the early diagnosis of RA and its personalized management

  • Assess the managed care considerations of biomarkers in the management of RA and the effect they have on the current moderate-to-severe RA management paradigm

  • Evaluate current evidence-based guidelines and their emphasis on early diagnosis and aggressive treatment for patients with RA

  • Explore available decision support tools with health plan affiliated rheumatology professionals to improve outcomes for patients with RA

     

Faculty: Jeffrey Curtis, MD, MS, MPH
Marguerite Jones Harbert
Gene Ball Endowed Professor of Medicine
UAB Division of Clinical Immunology & Rheumatology

Disclosure:

Dr. Curtis serves as a consultant and has received research/grant support from Amgen, Abbvie, BMS, Corrona, Lilly, Merck, Myriad, Novartis, Pfizer, Roche, Sanofi/Regeneron, Sandoz, Scipher, and Samsung
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Bristol-Myers Squibb

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue